Vanda Pharmaceuticals Inc (VNDA) — 13F Holders Deep Dive (Q2 2026)

VNDA ranks #3360 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

VNDA is a disclosed holding of Cliff Asness (AQR Capital Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

173 institutions disclose a position in VNDA, but none treat it as a major bet — even Krensavage Asset Management, LLC, its most concentrated holder, allocates just 2.7% of its own portfolio to it.

Cliff Asness has added to its VNDA position for two straight quarters, increasing it by $15.9M to reach $21.4M today.

BlackRock has trimmed its VNDA position for two straight quarters, cutting it by $21.7M while still holding $46.8M.

VNDA is up 2.1% today, and institutions have been net buyers of $33.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

VNDA reported a net loss of $274.9M over the trailing twelve months.

• Not yet profitable — net loss of $274.9M over the trailing twelve months
• Revenue grew 6.0% year over year
• Net income declined year over year, from -$66.9M to -$274.9M
• Operating cash flow was negative, using $109.4M in cash
• Current ratio of 2.39x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.49x equity — within a conventional range